- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08. | BioAffinity Technologies files to sell 12.61M shares of common stock for holders | 1 | Seeking Alpha | ||
| 29.08. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.08. | bioAffinity Technologies appoints two new directors to board | 1 | Investing.com | ||
| 14.08. | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | bioAffinity Technologies GAAP EPS of -$0.17, revenue of $1.3M | 1 | Seeking Alpha | ||
| 13.08. | bioAffinity Technologies, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 13.08. | bioAffinity Technologies raises $1.2 million in private placement | 4 | Investing.com | ||
| 13.08. | bioAffinity Technologies announces pricing of private placement | 1 | Seeking Alpha | ||
| 31.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.07. | bioAffinity Technologies sichert sich kanadisches Patent für Lungenkrebstest | 4 | Investing.com Deutsch | ||
| 22.07. | bioAffinity Technologies secures Canadian patent for lung cancer test | 1 | Investing.com | ||
| 15.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors | 3 | Insider Monkey | ||
| 27.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | bioAffinity Technologies names new chief medical officer | 2 | Investing.com | ||
| 20.05. | bioAffinity Technologies appoints Gordon Downie as chief medical officer | 2 | Seeking Alpha | ||
| 19.05. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,300 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,882 | +0,98 % | Ocugen, Inc. - 8-K, Current Report | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,900 | 0,00 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,465 | +4,73 % | Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,272 | -2,02 % | Vaxart, Inc.: Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors | ||
| BURCON NUTRASCIENCE | 1,520 | +7,04 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Puratein(R)C Canola Protein | Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| IDORSIA | 3,105 | +0,65 % | Idorsia Pharmaceuticals Ltd: Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension | Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patients
Allschwil, Switzerland & Radnor, Philadelphia... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,830 | -3,01 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Ampligen... ► Artikel lesen | |
| IMMUNIC | 0,640 | -1,08 % | EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in September | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor and Scientific Conferences in September
04.09.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
Das Unternehmen BIOAFFINITY TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-0,21 %) liegt der Kurs bei 0,239 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.